Financial Position - Fate Therapeutics reported 307millionincash,cashequivalents,andinvestments,providinganoperatingrunwayprojectedthroughtheendof2026[1].−Cashandcashequivalentsdecreasedto36,056,000 in 2024 from 41,870,000in2023,adeclineof14440,694,000 in 2024 from 506,217,000in2023,areductionof13318,726,000 in 2024 from 368,417,000in2023,adeclineof131.9 million, derived from preclinical development activities for a collaboration candidate targeting an undisclosed solid tumor antigen[10]. - Collaboration revenue for Q4 2024 was 1,860,000,anincreaseof111,676,000 in Q4 2023[15]. - Total operating expenses for Q4 2024 were 63.6million,including33.6 million in research and development expenses and 15.3millioningeneralandadministrativeexpenses[10].−TotaloperatingexpensesforQ42024were63,608,000, up 28% from 49,751,000inQ42023[15].−Researchanddevelopmentexpensesfortheyearended2024were135,001,000, down 22% from 172,596,000in2023[15].−Generalandadministrativeexpensesfortheyearended2024were74,169,000, a decrease of 9% from 81,448,000in2023[15].−NetlossforQ42024was52,153,000, compared to a net loss of 44,122,000inQ42023,representinganincreaseof181.64, unchanged from the previous year[15]. - The company reported an impairment loss of $14,737,000 in Q4 2024, with no impairment loss reported in Q4 2023[15]. Clinical Development - The Phase 1 dose expansion for FT819 in systemic lupus erythematosus (SLE) has been initiated, targeting up to 10 patients at a dose of 360 million cells[3]. - No dose-limiting toxicities or cytokine release syndrome were reported in the first three patients treated with FT819 for SLE[6]. - The FDA has approved the inclusion of additional B cell-mediated autoimmune diseases in the FT819 Phase 1 study, with plans to initiate dose-expansion cohorts in 2025[6]. - FT825, in collaboration with Ono Pharmaceutical, is advancing into higher-dose cohorts for advanced solid tumors, with ongoing enrollment at the third dose level of 900 million cells[2]. - Initial clinical data for FT825 showed a favorable safety profile with no dose-limiting toxicities in heavily pre-treated patients[7]. - The company is evaluating unique clinical development opportunities for FT522 in autoimmunity, with the FDA allowing an IND application for multiple B cell-mediated autoimmune diseases[10]. Shareholder Information - As of December 31, 2024, common shares outstanding were 113.9 million, with pre-funded warrants and preferred shares totaling 3.9 million and 2.8 million, respectively[10].
Fate Therapeutics(FATE)2025-03-05 21:02